Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.01M
Average 0.01M
CSBR Total Current Liabilities
All obligations due within one year.
Champions Oncology, Inc.NASDAQ: CSBR
Total Current Liabilities · Q3 FY2026 · quarter ended Jan 2026
Total current liabilities rises 4.1% from a year ago
Total current liabilities stood at $20.68M at the end of Q3 FY2026, up 4.1% from a year earlier and down 6.6% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Total current liabilities amounted to 72.7% of total assets at the end of Q3 FY2026, up 7.8 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +4.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 23.85M USD
- Year-over-year change
- +10.7%
- 4-year CAGR
- +20.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 23.85M | +10.7% |
| FY2024 | 2024-04-30 | 21.54M | -0.9% |
| FY2023 | 2023-04-30 | 21.73M | +24.3% |
| FY2022 | 2022-04-30 | 17.48M | +56.1% |
| FY2021 | 2021-04-30 | 11.2M | — |
Total Current Liabilities vs competitors
How CSBR compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +4.1% is the 4th highest of 10, against a peer median of -24.6%.
- Total current liabilities amounts to 72.7% of total assets for CSBR, versus a peer median of 10.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $70.81M USD | -46.8% | +4.1% | 29.3% | |
| Jan 2026 | $20.68M USD | +4.1% | +10.9% | 72.7% | |
| Dec 2025 | $13.61M USD | +60.9% | -4.5% | 24.3% | |
| Mar 2026 | €11.4M EUR | -29.6% | -0.1% | 23.3% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $10.88M USD | -10.8% | -20.1% | 10.3% |
| Mar 2026 | $10.56M USD | +92.3% | +49.2% | 3.9% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $8.08M USD | +13.1% | +19.5% | 7.4% |
IMAImageneBio Inc | Mar 2026 | $6.63M USD | -24.6% | -19.5% | 4.9% |
| Mar 2026 | $5.65M USD | -88.2% | -42.6% | 28.2% | |
| Mar 2026 | $4.25M USD | -41.9% | -34.4% | 4.2% | |
| Peer median (excluding CSBR) | — | -24.6% | -4.5% | 10.3% | |
Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.69M | 9.01M | 10.12M | 2.62M | 9.79M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 6.99M | 9.51M | 8.01M | 9.53M | 11.23M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 1.33M | 1.5M | 1.35M |
| Total Current Assets | 12.63M | 19.66M | 19.46M | 13.64M | 22.37M |
| Property, Plant & Equipment (Net) | 14.61M | 15.36M | 14.5M | 11.97M | 9.46M |
| Goodwill | 335K | 335K | 335K | 335K | 335K |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 15K | 15K | 15K | 185K | 185K |
| Total Non-current Assets | 14.96M | 15.71M | 14.85M | 12.49M | 9.98M |
| Total Assets | 27.59M | 35.38M | 34.31M | 26.13M | 32.34M |
| Account Payables | 1.89M | 2.87M | 5.33M | 5.8M | 4.25M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6.26M | 11.07M | 12.78M | 12.09M | 15.44M |
| Other Current Liabilities | 0 | 72K | 145K | 150K | 135K |
| Total Current Liabilities | 11.2M | 17.48M | 21.73M | 21.54M | 23.85M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 181K | 391K | 551K | 401K | 85K |
| Total Non-current Liabilities | 8.96M | 8.8M | 7.94M | 6.49M | 4.72M |
| Total Liabilities | 20.16M | 26.28M | 29.68M | 28.04M | 28.57M |
| Common Stock | 13K | 14K | 14K | 14K | 14K |
| Retained Earnings | (72.53M) | (71.98M) | (77.32M) | (84.59M) | (79.89M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 7.43M | 9.1M | 4.64M | (1.9M) | 3.77M |
| Total Debt | 9.6M | 9.47M | 8.6M | 7.43M | 6.11M |
| Net Debt | 4.91M | 459K | (1.52M) | 4.81M | (3.68M) |
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.